Company files patent on ‘extinct’ animal

The US company Colossal Biosciences claims so-called ‘dire wolf’ as an invention

21 October 2026

The US company Colossal Biosciences has filed a patent application for the so-called ‘dire wolf’. Under patent number WO2026156231, the company is claiming genetically engineered wolves in which about a dozen gene functions have been altered as its ‘invention’. Among other things, the animals are said to differ from existing wolf populations in terms of size, coat colour and whiskers. The genetically engineered wolves are meant to resemble an extinct wolf species, although the similarity is mostly imagined.

The patent claims specific gene variants that influence the appearance of the animals, as well as the genetically engineered wolves themselves. According to the patent, similar genetic alterations could be applied in over 20 wild species, including wolves, foxes, jackals, coyotes and wild dogs.

By filing this patent application, the company is entering an ethically questionable terrain. The patent could become an economic incentive to conduct experiments that cause pain and suffering to the animals.

In addition to new genetic engineering, cloning methods were used in the experiments which are known to be associated with high rates in animal mortality and severe suffering. As stated in the patent specification, the experiments produced 339 ‘transgenic’ wolf embryos, resulting in only two animals being born in 2024. A third animal is the outcome of further experiments. The embryos were carried to term by female dogs that served as surrogate mothers. It is known that such surrogate mothers are exposed to considerable stress and health risks. Keeping the genetically engineered wolves, which are to remain confined for life, also raises questions from an ethical and welfare perspective.

The Colossal Foundation, which describes itself as a nonprofit branch of Colossal Biosciences, just recently announced that it would provide $4 million in funding for a joint project with the International Union for Conservation of Nature (IUCN). The project focuses on “innovative” species conservation and will utilize new technologies and artificial intelligence. Given Colossal Biosciences’ current activities, this initiative raises various questions. For example, whether the company could obtain exclusive rights to use genomic data from wild species in order to file additional patents.

The US company Colossal Biosciences says it wants to ‘bring back to life’ extinct vertebrates, such as woolly mammoths, dire wolves and dodos. In reality the company is using genetic engineering and artificial intelligence to create genetically engineered versions of existing wild life species, e.g. Asian elephants, grey wolves, South American birds and mice with ‘woolly mammoth fur’.

These experiments do not amount to “bringing extinct animal species back to life”, but rather creating genetically engineered animals that have never previously existed on this planet. The projects also pose significant risks to species conservation if, for example, genetically engineered animals, such as ‘dire wolves’ escape and reproduce in natural populations.

Contact:

Christoph Then, Tel + 49 (0)151 54638040, info@testbiotech.org

Further information:

The ‘dire wolf’ patent

The cooperation with IUCN